|Dr. Thomas J. Schall Ph.D.||Founder, Pres, CEO & Chairman||909.17k||2.09M||1959|
|Ms. Susan M. Kanaya||Exec. VP, Chief Financial & Admin. Officer and Sec.||656.68k||1.16M||1963|
|Dr. Rajinder Singh||Sr. VP & Head of Pharmaceutics||465.34k||N/A||1967|
|Dr. Markus J. Cappel||Sr. VP, Chief Bus. Officer & Treasurer||546.4k||924.2k||1961|
|Dr. Catherine Lee Kelleher||Sr. VP of Clinical Devel.||N/A||N/A||N/A|
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. The company is also developing Avacopan for the treatment of patients with complement 3 glomerulopathy and hidradenitis suppurativa. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis. Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.
ChemoCentryx, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 5; Compensation: 9.